Curat Global’s Pfizer PFE Stock Holding History

Curat Global’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$788K	Sell	28,763 -6,540	-19%	-$171K	0.64%	35
2026 Q1	$991K	Buy	35,303 +19,945	+130%	+$531K	0.98%	21
2025 Q4	$382K	Sell	15,358 -20,195	-57%	-$509K	0.42%	62
2025 Q3	$901K	Hold	35,553	–	–	0.85%	26
2025 Q2	$862K	Buy	35,553 +7,308	+26%	+$170K	0.82%	27
2025 Q1	$716K	Buy	+28,245	New	+$739K	0.87%	32

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Curat Global's PFE Position: Q2 2026 in Review

Curat Global reduced its Pfizer (PFE) stake by 19% in Q2 2026, selling an estimated $171K and leaving 28,763 shares worth $788K. The position accounts for 0.64% of the portfolio, ranked #35.

Curat Global first reported a position in PFE in Q1 2025 and has held it in 6 quarters since. The position peaked at $991K in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Curat Global held 28,763 shares of Pfizer worth $788K as of Q2 2026.
Curat Global sold 6,540 Pfizer shares in Q2 2026, an estimated $171K.
Pfizer made up 0.64% of Curat Global's portfolio in Q2 2026, its #35 holding.
Curat Global first reported a position in Pfizer in Q1 2025 and has held it in 6 quarters since.
Curat Global's Pfizer position peaked at $991K in Q1 2026.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Curat Global's 13F filing for Q2 2026, filed 22 Jul 2026.